Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.
Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.
复制标题
DOI：
10.1111/j.1601-5215.2011.00634.x
复制
发表时间：
2012-06
影响因子：
3.8
通讯作者：
Feifel D
中科院分区：
文献类型：
--
作者：
Macdonald K;Feifel D
神经激素催产素可能在精神分裂症治疗中有临床应用的建议于1972年首次发表。从那时起，在各个方面的大量研究——包括最近的几项双盲治疗试验——都支持了这些早期的报告，为催产素系统是治疗这种毁灭性疾病的一个有希望的新靶点的断言提供了支持。在此，我们回顾了不同的，趋同的证据线支持催产素在精神疾病的治疗潜力。我们对有关催产素在精神分裂症中的作用的临床前和临床文献进行了系统的回顾。多种证据汇聚在一起，支持催产素的抗精神病潜能。这些研究包括若干精神分裂症动物模型、检查抗精神病药物对催产素系统影响的药理学研究、检查催产素系统各方面的患者人体试验以及若干双盲、安慰剂对照的临床治疗试验。有相当多的证据表明，催产素具有作为一种具有独特作用机制的新型抗精神病药物的潜力。幸运的是，根据迄今为止少数的慢性试验，其安全性和耐受性似乎非常好。也就是说，在临床上广泛使用之前，有几个关键的临床问题有待调查。
The suggestion that the neurohormone oxytocin may have clinical application in the treatment of schizophrenia was first published in 1972. Since then, a considerable body of research on a variety of fronts--including several recent double-blind treatment trials—has buttressed these early reports, providing support for the assertion that the oxytocin system is a promising and novel therapeutic target for this devastating malady. Herein, we review the diverse, convergent lines of evidence supporting the therapeutic potential of oxytocin in psychotic illness. We performed a systematic review of preclinical and clinical literature pertaining to oxytocin’s role in schizophrenia. Multiple lines of evidence converge to support the antipsychotic potential of oxytocin. These include several animal models of schizophrenia, pharmacological studies examining the impact of antipsychotics on the oxytocin system, human trials in patients examining aspects of the oxytocin system, and several double-blind, placebo-controlled clinical treatment trials. There exists considerable, convergent evidence that oxytocin has potential as a novel antipsychotic with a unique mechanism of action. Auspiciously, based on the few chronic trials to date, its safety profile and tolerability appear very good. That said, several critical clinical questions await investigation before widespread use is clinically warranted.
登录
查看更多内容
影响因子：
5.3
作者：
Bale, TL;Davis, AM;McCarthy, MM
通讯作者：
McCarthy, MM
影响因子：
3.4
作者：
Baskerville, T. A.;Allard, J.;Douglas, A. J.
通讯作者：
Douglas, A. J.
影响因子：
--
作者：
Bakharev, V D;Tikhomirov, S M;Lozhkina, T K
通讯作者：
Lozhkina, T K
影响因子：
3.7
作者：
BECKMANN, H;LANG, RE;GATTAZ, WF
通讯作者：
GATTAZ, WF
影响因子：
2.9
作者：
BUIJS, RM;VANHEERIKHUIZE, JJ
通讯作者：
VANHEERIKHUIZE, JJ